X
<

Where Sanofi Stands after the 3Q17 Results

PART:
1 2 3 4 5 6 7 8
Part 8
Where Sanofi Stands after the 3Q17 Results PART 8 OF 8

How Did Sanofi Pasteur Perform in 3Q17?

Sanofi Pasteur

Sanofi Pasteur represents the human vaccines business of Sanofi (SNY). Sanofi Pasteur includes vaccines from the following therapeutics areas:

  • adult boosters
  • dengue
  • influenza
  • meningitis
  • polio and pertussis
  • travel and other endemic vaccines

 

How Did Sanofi Pasteur Perform in 3Q17?

Interested in SNY? Don't miss the next report.

Receive e-mail alerts for new research on SNY

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Sanofi Pasteur reported revenues of 1.92 billion euros for 3Q17, which was 11% higher YoY (year-over-year) at constant exchange rates. These revenues were impacted positively by a 68.9% rise in European sales to 199 million euros as a result of the termination of the joint venture between Sanofi Pasteur and Merck (MRK) in 2016.

Adult and booster vaccines

The adult booster vaccine franchise reported a 42.3% YoY rise in revenues at constant exchange rates to 143 million euros in 3Q17, driven by 29.3% growth in US sales to 92 million euros and ~230% growth in European sales to 37 million euros. These gains were offset by lower sales in emerging markets and the rest of the world.

Dengue and influenza

Dengue vaccines reported revenues of 4 million euros for 3Q17, which was 90% lower YoY at constant exchange rates.

Influenza vaccines reported a 1% YoY rise in revenues at constant exchange rates to 951 million euros, driven by increased US sales and revenues from the rest of the world, substantially offset by lower sales in European markets and emerging markets.

Meningitis and pneumonia vaccines

Meningitis and pneumonia vaccines reported 3.9% YoY growth in revenues at constant exchange rates to 252 million euros for 3Q17, driven by 1.4% growth in US sales to 213 million euros and 14.3% growth in revenues from emerging markets to 32 million euros.

Polio, Pertussis, HIB vaccines

Polio, pertussis, and HIB vaccines reported 38.6% YoY growth in revenues at constant exchange rates to 433 million euros for 3Q17. This growth was driven by strong US sales, European sales, and emerging market sales, partially offset by lower sales in the rest of the world.

Travel and other endemics vaccines

Travel and other endemics vaccines reported a 53.2% YoY rise in revenues at constant exchange rates to 114 million euros for 3Q17. This growth was driven by strong sales across US and European markets and nearly flat emerging market sales.

Notably, the BLDRS Developed Markets 100 ADR ETF (ADRD) has 2.5% of its total assets in Sanofi ADR (SNY), 2.1% in Novo Nordisk (NVO), 2.0% in AstraZeneca ADR (AZN), and 0.3% in Teva Pharmaceutical ADR (TEVA).

X

Please select a profession that best describes you: